Corcept Therapeutics Incorporated (NASDAQ:CORT) is reporting third quarter financial results on Tuesday 3rd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, CORT is expected to report 3Q20 income of $ 0.20 per share from revenue of $ 90.87 million.
For the full year, analysts anticipate top line of $ 366.22 million, while looking forward to income of $ 0.86 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 355.00 million ~ $ 375.00 million
Click Here For More Historical Outlooks Of Corcept Therapeutics Incorporated
Previous Quarter Performance
Corcept Therapeutics Incorporated revealed income for the second quarter of $ 0.32 per share, from the revenue of $ 88.56 million. The quarterly earnings raised 88.24 percent while revenues improved 24.94 percent compared with the same quarter last year.
Wall street analysts are predicting, CORT to report 2Q20 income of $ 0.22 per share from revenue of $ 90.14 million. The bottom line results beat street analysts by $ 0.1 or 45.45 percent, at the same time, top line results fell short of analysts by $ 1.58 million or 1.75 percent.
Stock Performance
Shares of Corcept Therapeutics Incorporated traded up $ 0.63 or 3.75 percent on Monday, reaching $ 17.41 with volume of 1.17 million shares. Corcept Therapeutics Incorporated has traded high as $ 17.42 and has cracked $ 16.67 on the downward trend
The closing price of $ 17.41, representing a 72.99 % increase from the 52 week low of $ 9.70 and a 28.53 % decrease over the 52 week high of $ 23.48.
The company has a market capital of $ 2.01 billion and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Corcept Therapeutics Incorporated will be hosting a conference call at 5:00 PM eastern time on 3rd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.corcept.com
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushings syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors.
